Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MST1R dec exp |
| Therapy | Doxorubicin |
| Indication/Tumor Type | bladder carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R dec exp | bladder carcinoma | predicted - sensitive | Doxorubicin | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Adriamycin (doxirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202). | 26772202 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26772202) | RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs. | Full reference... |